[Disclosure] Samsung Biologics(207940) Reports Q1 2024 Operating Profit of KRW 221.3B, Up 15.41% YoY

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2024-04-24

Disclosure Type: Operating Performance (Preliminary) Based on Consolidated Financial Statements (Fair Disclosure)

💡 3-Second Summary

Samsung Biologics announced its preliminary consolidated financial results for Q1 2024, with operating profit rising 15.41% YoY to KRW 221.3 billion and revenue increasing 31.35% YoY to KRW 946.9 billion. However, compared to the previous quarter (Q4 2023), revenue and operating profit decreased by 11.79% and 36.77%, respectively.

📊 1. [Summary of Core Disclosure Content and Major Figures]

• Q1 2024 Financial Performance and Growth Rates (Consolidated):
  • Revenue: KRW 946,903M (Approx. KRW 946.9B)
    • QoQ (vs. Q4 2023): Decreased by 11.79%
    • YoY (vs. Q1 2023): Increased by 31.35%
  • Operating Profit: KRW 221,299M (Approx. KRW 221.3B)
    • QoQ (vs. Q4 2023): Decreased by 36.77%
    • YoY (vs. Q1 2023): Increased by 15.41%
  • Profit Before Income Tax: KRW 240,077M (Approx. KRW 240.1B)
    • QoQ: Decreased by 32.51% / YoY: Increased by 22.08%
  • Net Profit: KRW 179,362M (Approx. KRW 179.4B)
    • QoQ: Decreased by 38.30% / YoY: Increased by 26.53%
• Cumulative Figures: Due to the nature of the first quarter, the quarterly results match the cumulative year-to-date metrics (Revenue of KRW 946.9B and Operating Profit of KRW 221.3B).
• Note: These financial metrics are preliminary figures prepared before the completion of the external auditor’s review and are subject to change based on the final audit outcomes.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

• Impact on Fundamental Changes: Compared to the same period last year (Q1 2023), revenue expanded by 31.35% and operating profit rose by 15.41%, indicating that the company’s annual operational scale and baseline earnings capacity continue to track on an upward path. Conversely, the double-digit deceleration in both revenue and profit metrics on a QoQ basis highlights notable sequential fluctuations between individual quarters. In terms of structural earnings matching, revenue remains safely higher than operating profit, cross-checking correctly.
• Risks and Red Flags for Investors: The regulatory filing does not specify the concrete reasons behind the observed YoY expansion or the sequential QoQ reduction in performance metrics (such as plant utilization rates, manufacturing campaign schedules, or subsidiary contributions). Consequently, market participants should refrain from forming speculative conclusions based on external assumptions. Furthermore, as these figures represent unreviewed preliminary data, investors may want to consider the potential impact of minor adjustments when the audited reports are finalized.

📝 Editor’s Comment (by K-STOCK Editor)

Samsung Biologics’ initial scorecard for the year confirms robust top-line growth on a YoY basis, though it indicates a temporary sequential slowdown compared to the preceding quarter. Because the disclosure does not explain the explicit operational causes for these fluctuations, market participants may adopt a watchful stance ahead of the details to be released via investor relations channels or the corporate website. Given that preliminary figures are subject to minor modifications during the external audit process, taking an objective approach that tracks long-term historical trends rather than reacting abruptly to immediate sequential shifts could be the most balanced analytical strategy.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on official submission data from the Financial Supervisory Service’s Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided for informational and linguistic reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest solely with the investor.

Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.